Nomogram construction for predicting survival of patients with non‑small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268 patients

Tian,Tian; Zhang,Pengpeng; Zhong,Fei; Sun,Cuiling; Zhou,Jian; Hu,Wenjun

doi:10.3892/ol.2019.11112

Nomogram construction for predicting survival of patients with non‑small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268 patients

Authors:
- Tian Tian
- Pengpeng Zhang
- Fei Zhong
- Cuiling Sun
- Jian Zhou
- Wenjun Hu
View Affiliations

Affiliations: Department of Medical Oncology, Fuyang People's Hospital, Fuyang, Anhui 236000, P.R. China, Medical Imaging Center, Fuyang Second People's Hospital, Fuyang, Anhui 236000, P.R. China, Department of Medical Oncology, Affiliated Fuyang Hospital of Anhui Medical University, Fuyang, Anhui 236000, P.R. China
Published online on: November 19, 2019 https://doi.org/10.3892/ol.2019.11112
Pages: 449-459
Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Determining the accurate outcome of patients with non‑small cell lung cancer (NSCLC) and malignant pleural effusion (MPE) or malignant pleural pericardial effusion (MPCE) at the initial diagnosis remains a challenge. The aim of the present study was to develop an effective nomogram for individualized estimation of overall survival in these patients. Patients diagnosed between January 2010 and December 2015 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Age, race, sex, grade, histology, laterality, stage and status of MPE or MPCE at initial diagnosis were included as covariates. Several survival models were created and the performance of each was evaluated. The most effective model was then validated by internal bootstrap resampling and by using an independent external cohort. A nomogram was created based on this survival model and the predictive accuracy of the nomogram was evaluated by calibration plots. Data from 10,268 patients with lung cancer with MPE or MPCE at initial diagnosis were collected. The multivariate analysis with a lognormal model suggested that age, race, sex, histology, stage and status of MPE or MPCE at initial diagnosis were significant independent factors to predict survival. A nomogram was constructed based on the lognormal survival model, which showed the best performance. The concordance index of the survival model in the SEER cohort was 0.736. Both internal and external validation showed an acceptable level of agreement between the nomogram‑predicted survival probability and actual survival. The nomogram of the present study based on a large cohort from the SEER database may improve prognostic prediction of patients with NSCLC with MPE or MPCE at initial diagnosis, and allow physicians to make appropriate decisions for disease management of their patients.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Abisheganaden J, Verma A, Dagaonkar RS and Light RW: An observational study evaluating the performance of LENT score in the selected population of malignant pleural effusion from lung adenocarcinoma in Singapore. Respiration. 96:308–313. 2018. View Article : Google Scholar : PubMed/NCBI
4	Ou SH and Zell JA: Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California cancer registry. J Thorac Oncol. 3:216–227. 2008. View Article : Google Scholar : PubMed/NCBI
5	Roberts ME, Neville E, Berrisford RG, Antunes G and Ali NJ; BTS Pleural Disease Guideline Group, : Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax. 65 (Suppl 2):ii32–ii40. 2010. View Article : Google Scholar : PubMed/NCBI
6	Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, et al: Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): A multicohort analysis. Lancet Oncol. 19:930–939. 2018. View Article : Google Scholar : PubMed/NCBI
7	Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ET, Tobin CL, et al: Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score. Thorax. 69:1098–1104. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bildirici U, Celikyurt U, Acar E, Bulut O, Sahin T, Kozdag G and Ural D: The value of serum tumour markers in the prediction of aetiology and follow up of patients with pericardial effusion. Cardiovasc J Afr. 23:143–146. 2012. View Article : Google Scholar : PubMed/NCBI
9	Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, Kim JS and Thomas CR Jr: Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 29:4627–4632. 2011. View Article : Google Scholar : PubMed/NCBI
10	Eil R, Diggs BS, Wang SJ, Dolan JP, Hunter JG and Thomas CR: Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: A SEER-Medicare analysis. Cancer. 120:492–498. 2014. View Article : Google Scholar : PubMed/NCBI
11	Vergouwe Y, Steyerberg EW, Eijkemans MJ and Habbema JD: Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol. 58:475–483. 2005. View Article : Google Scholar : PubMed/NCBI
12	DeLong ER, DeLong DM and Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 44:837–845. 1988. View Article : Google Scholar : PubMed/NCBI
13	Porcel JM, Gasol A, Bielsa S, Civit C, Light RW and Salud A: Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 20:654–659. 2015. View Article : Google Scholar : PubMed/NCBI
14	Mbeutcha A, Mathieu R, Rouprêt M, Gust KM, Briganti A, Karakiewicz PI and Shariat SF: Predictive models and prognostic factors for upper tract urothelial carcinoma: A comprehensive review of the literature. Transl Androl Urol. 5:720–734. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yang L, Wang S, Zhou Y, Lai S, Xiao G, Gazdar A and Xie Y: Evaluation of the 7th and 8th editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget. 8:66784–66795. 2017.PubMed/NCBI
16	Tian T, Li J, Hu W, Sun C and Zhou J: Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion. J Clin Lab Anal. 33:e229012019. View Article : Google Scholar : PubMed/NCBI
17	Psallidas I, Kalomenidis I, Porcel JM, Robinson BW and Stathopoulos GT: Malignant pleural effusion: From bench to bedside. Eur Respir Rev. 25:189–198. 2016. View Article : Google Scholar : PubMed/NCBI
18	Liu YY: Influencing factors and combined application of chemiluminescence immunoassay for detection of tumor markers. Clin Lab J. 1:1432019.
19	Ren S, Kuang P, Zheng L, Su C, Li J, Li B, Chen X, Wang Y, KimCurran V, Liu L, et al: Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys. 64:155–160. 2012. View Article : Google Scholar : PubMed/NCBI
20	Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
21	Midha A, Dearden S and McCormack R: EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
22	Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, et al: Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 29:3316–3321. 2011. View Article : Google Scholar : PubMed/NCBI
23	Iasonos A, Schrag D, Raj GV and Panageas KS: How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 26:1364–1370. 2008. View Article : Google Scholar : PubMed/NCBI
24	Van Belle V and Van Calster B: Visualizing risk prediction models. PLoS One. 10:e01326142015. View Article : Google Scholar : PubMed/NCBI
25	Du F: Differentiation antigen expression and lung cancer heterogeneity. J Clin Exp Pathol. 2:200–203. 2002.
26	Chen VW, Ruiz BA, Hsieh MC, Wu XC, Ries LA and Lewis DR: Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 120 (Suppl 23):3781–3792. 2014. View Article : Google Scholar : PubMed/NCBI
27	Dixit R, Agarwal KC, Gokhroo A, Patil CB, Meena M, Shah NS and Arora P: Diagnosis and management options in malignant pleural effusions. Lung India. 34:160–166. 2017. View Article : Google Scholar : PubMed/NCBI
28	Zamboni MM, da Silva CT Jr, Baretta R, Cunha ET and Cardoso GP: Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 15:292015. View Article : Google Scholar : PubMed/NCBI
29	Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
30	Ballman KV: Biomarker: Predictive or prognostic? J Clin Oncol. 33:3968–3971. 2015. View Article : Google Scholar : PubMed/NCBI
31	Vickers AJ and Cronin AM: Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology. 76:1298–1301. 2010. View Article : Google Scholar : PubMed/NCBI